Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

67.01
+1.542.35%
Post-market: 67.020.0100+0.01%19:59 EDT
Volume:6.84M
Turnover:457.82M
Market Cap:136.42B
PE:14.75
High:67.55
Open:65.79
Low:65.13
Close:65.47
52wk High:68.64
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:0.72
T/O Rate:0.34%
Dividend:2.51
Dividend Rate:3.74%
EPS(TTM):4.54
EPS(LYR):3.46
ROE:46.60%
ROA:10.72%
PB:6.11
PE(LYR):19.37

Loading ...

Balanced Risk-Reward Keeps Bristol-Myers Squibb at Hold as Zenbexus CELMoD Opportunity Awaits Key 2026 Data

TIPRANKS
·
Aug 14

Heart Drug Developer Atrium Therapeutics' Q2 Loss Widens as Expenses Rise

Reuters
·
Aug 14

FDA Grants Accelerated Approval to Bristol Myers Squibb’s Zenbexus for Relapsed Multiple Myeloma Combo Use

Reuters
·
Aug 14

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First Celmod Therapy Zenbexus™, in Combination with Daratumumab and Hyaluronidase-Fihj and Dexamethasone (Zdd) for Patients with Multiple Myeloma, as Early as First Relapse

THOMSON REUTERS
·
Aug 14

Bristol-Myers Squibb - Zenbexus Available Only Through Restricted Zenbexus Rems Program

THOMSON REUTERS
·
Aug 14

Bristol Myers Squibb Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 14

US FDA Approves Bristol Myers' Blood Cancer Treatment

Reuters
·
Aug 14

FDA Grants Accelerated Approval to Iberdomide with Daratumumab and Hyaluronidase-Fihj and Dexamethasone for Multiple Myeloma

THOMSON REUTERS
·
Aug 14

Cytokinetics - Files Complaint Against Bristol-Myers Squibb and Myokardia - SEC Filing

THOMSON REUTERS
·
Aug 13

Cytokinetics - Demands Trial by Jury on All Triable Issues - SEC Filing

THOMSON REUTERS
·
Aug 13

Cytokinetics Sues Bristol Myers, MyoKardia Seeking Ruling on Myqorzo Patent Dispute

Reuters
·
Aug 13

Atrium Gets $15M in Latest Milestone Payment from Bristol Myers Squibb

Dow Jones
·
Aug 13

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

THOMSON REUTERS
·
Aug 13

Atrium Therapeutics - Eligible for up to $1.35 Bln R&D Milestones, $825 Mln Commercial Milestones, Tiered Royalties

THOMSON REUTERS
·
Aug 13

Atrium Therapeutics - Bristol Myers Squibb to Fund All Future Development and Commercialization Activities

THOMSON REUTERS
·
Aug 13

Switzerland's PolyPeptide H1 Revenue Rises on Stronger Metabolic Therapeutics Demand

Reuters
·
Aug 13

Why Bristol Myers Squibb (BMY) Is Back In The Spotlight

Simply Wall St.
·
Aug 13

BMY Expands Melanoma Immunotherapy Footprint With New Phase 4 Trial in India

TIPRANKS
·
Aug 13

Huang's $500 Billion Financing Plan Splits Markets: Asset Managers Rally as Tech Stocks Slide for Second Day

Deep News
·
Aug 12

Bristol Myers Squibb Co. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Aug 12